Bruker Corporation $BRKR Shares Acquired by Sector Gamma AS

Sector Gamma AS lifted its position in Bruker Corporation (NASDAQ:BRKR) by 28.0% during the third quarter, HoldingsChannel.com reports. The fund owned 250,909 shares of the medical research company’s stock after acquiring an additional 54,939 shares during the period. Bruker makes up 2.0% of Sector Gamma AS’s portfolio, making the stock its 18th largest position. Sector Gamma AS’s holdings in Bruker were worth $8,152,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd acquired a new stake in Bruker during the 2nd quarter worth $192,735,000. AQR Capital Management LLC grew its stake in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Sculptor Capital LP grew its stake in Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after acquiring an additional 476,363 shares in the last quarter. Brown Advisory Inc. raised its holdings in Bruker by 13.9% in the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock valued at $113,142,000 after acquiring an additional 336,026 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its stake in Bruker by 61.6% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock worth $67,909,000 after purchasing an additional 796,510 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, VP Mark Munch sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $55.00, for a total value of $385,000.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at $7,064,365. This trade represents a 5.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John A. Ornell sold 6,233 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the transaction, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. This trade represents a 15.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 15,233 shares of company stock valued at $726,487. 27.30% of the stock is currently owned by company insiders.

Bruker Stock Down 3.4%

NASDAQ:BRKR opened at $50.33 on Friday. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $59.40. The stock’s fifty day moving average is $48.08 and its two-hundred day moving average is $40.33. The stock has a market capitalization of $7.65 billion, a price-to-earnings ratio of -314.56, a price-to-earnings-growth ratio of 6.62 and a beta of 1.17. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The firm had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the previous year, the business earned $0.60 EPS. The company’s quarterly revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Research analysts anticipate that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Stockholders of record on Monday, December 8th were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s dividend payout ratio is currently -125.00%.

Analyst Ratings Changes

A number of research firms have recently issued reports on BRKR. Redburn Partners set a $60.00 price target on Bruker in a research report on Thursday, November 20th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research note on Monday, December 29th. Barclays lifted their price target on Bruker from $45.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. TD Cowen reissued a “hold” rating on shares of Bruker in a report on Wednesday, January 7th. Finally, Citigroup lifted their target price on shares of Bruker from $40.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $53.36.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.